Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$319.56 USD

319.56
307,956

+5.34 (1.70%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medpace (MEDP) Tops Q3 Earnings Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 8.66% and 1.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the most recent trading session, Medpace (MEDP) closed at $347.91, indicating a +0.93% shift from the previous trading day.

Medpace (MEDP) Laps the Stock Market: Here's Why

by Zacks Equity Research

Medpace (MEDP) reachead $343.05 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.

SOLV or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SOLV vs. MEDP: Which Stock Is the Better Value Option?

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

In the latest trading session, Medpace (MEDP) closed at $326.26, marking a +1.77% move from the previous day.

Medpace (MEDP) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

The latest trading day saw Medpace (MEDP) settling at $354.65, representing a -0.57% change from its previous close.

Is Medpace (MEDP) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Medpace (MEDP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

HQY vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

HQY vs. MEDP: Which Stock Is the Better Value Option?

Medpace (MEDP) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

In the latest trading session, Medpace (MEDP) closed at $339.38, marking a +1.08% move from the previous day.

Medpace (MEDP) Stock Moves -1.52%: What You Should Know

by Zacks Equity Research

In the most recent trading session, Medpace (MEDP) closed at $349.87, indicating a -1.52% shift from the previous trading day.

SGRY or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SGRY vs. MEDP: Which Stock Is the Better Value Option?

3 Reasons Growth Investors Will Love Medpace (MEDP)

by Zacks Equity Research

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Medpace (MEDP) Tops Q2 Earnings Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 9.13% and 0.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings

by Zacks Equity Research

Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.

Shaun Pruitt headshot

Top Stocks to Buy for Growth as Earnings Approach

by Shaun Pruitt

Investors will want to pay attention to several top-rated Zacks stocks that are set to report their quarterly results on Monday, July 22.

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.

Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SGRY vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

SGRY vs. MEDP: Which Stock Is the Better Value Option?

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

The latest trading day saw Medpace (MEDP) settling at $443, representing a +1.84% change from its previous close.

Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches

by Zacks Equity Research

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?

by Zacks Equity Research

Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.

Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial

by Zacks Equity Research

Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.

Medpace (MEDP) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Hyperfine (HYPR) Inks New Partnerships to Expand in Europe

by Zacks Equity Research

Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.